The SGLT-2 diabetes treatment has expanded its indication to other treatments for diseases such as heart failure. In Korea, AstraZeneca's Forxiga (Dapagliflozin Propanediol Hydrate) has also been recognized for its efficacy and effect on chronic heart failure and chronic kidney disease. And Boehringer Ingelheim's "Jardiance (Empagliflozin)" is also expanding his indication.

EMPACT-MI, which is currently undergoing multinational clinical research, is also a test to seek other treatments for diseases. The MFDS approved the EMPACT-MI (clinical phase 3) for domestic subjects on the 24th. This test is for patients with acute myocardial infarction for hospitalization and death due to heart failure. A test to